Comparative Pharmacology
Head-to-head clinical analysis: KOROSTATIN versus OMTRYG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KOROSTATIN versus OMTRYG.
KOROSTATIN vs OMTRYG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KOROSTATIN is a direct thrombin inhibitor that binds reversibly to the active site of thrombin, blocking its interaction with substrates and thereby inhibiting fibrin formation, platelet activation, and coagulation cascade amplification.
OMTRYG is a combination of ombitasvir, paritaprevir, and ritonavir. Ombitasvir is an NS5A inhibitor that blocks viral RNA replication and assembly. Paritaprevir is an NS3/4A protease inhibitor that prevents viral polyprotein cleavage. Ritonavir is a CYP3A4 inhibitor used to boost paritaprevir levels.
50 mg orally twice daily
2 mg orally twice daily; if taste disturbance occurs, reduce to 1 mg twice daily.
None Documented
None Documented
8-12 hours in normal renal function; prolonged to 24-36 hours in severe renal impairment (CrCl <30 mL/min)
Terminal elimination half-life is 12-14 hours in healthy adults, allowing once-daily dosing. In renal impairment (CrCl <30 mL/min), half-life prolongs to 24-36 hours requiring dose adjustment.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Primarily renal excretion unchanged (approximately 70%), with 30% metabolized hepatically and excreted in feces via bile. Renal clearance accounts for ~60% of total clearance.
Category C
Category C
HMG-CoA Reductase Inhibitor (Statin)
HMG-CoA Reductase Inhibitor (Statin)